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Comparative analysis of the Clostridium difﬁcile BI/NAP1/027 strain R20291 and ClosTron-derived ermB
mutants in the hamster infection model are compromised by the clindamycin susceptibility of the
parent. Mutants can appear more virulent. We have rectiﬁed this anomaly by genome engineering. The
variant created (CRG20291) represents an ideal control strain for virulence assays of ClosTron mutants.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Clostridium difﬁcile is the leading cause of healthcare associated
diarrhoea, causing almost half a million cases of C. difﬁcile infection
(CDI) in the United States in 2011 and 13,783 cases in the UK in 2014
[1,2]. The situation has been exacerbated by the emergence of
epidemic strains, and in particular BI/NAP1/027 strains typiﬁed by
strain R20291 [3,4]. Its use in the Golden Syrian hamster, the in vivo
model of choice for infection studies [5], is complicated by the
sensitivity of R20291 to clindamycin (Minimum Inhibitory Con-
centration, MIC ¼ 16 mg/ml) [6]. Hamsters are dosed with clinda-
mycin prior to infection with C. difﬁcile to disrupt the normal gut
ﬂora. Clindamycin can persist at inhibitory levels (4e6 mg/g) some
11 days following administration [7], and has been shown to affect
the time from infection to colonisation and death of strains with
different clindamycin MICs [8]. One consequence is that ClosTron-
generated mutants of R20291 in the hamster can show symptoms
and succumb to disease earlier than those infected with the parentup, BBSRC/EPSRC Synthetic
es, University of Nottingham,
om.
.P. Minton).
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r Ltd. This is an open access article[9], a consequence of the introduction of the ermB gene during the
mutagenesis.
A solution to the problem would be an ermB variant of R20291
which could be used as the isogenic, parental control in hamster
assays of virulence that is otherwise unaffected in any other
physiological characteristics. To create such a strain we synthesised
the ermB gene of pMTL007C-E1 [10] such that it was immediately
preceded by a sequence encompassing a clostridial thiolase gene
promoter (Pthl) and beginning with a NotI restriction site and was
followed after its translational stop codon by a HindIII restriction
site (see supplementary ﬁle). This appropriately cleaved DNA
fragment was cloned between the NotI and HindIII restriction sites
of the ACE (Allele-Coupled Exchange, [11]) complementation vector
pMTL-YN2C [12] and the resultant plasmid (pMTL-YN2C:ermB)
used to restore the previously made R20291 pyrE mutant
(CRG2358) to prototrophy as previously described [12]. A DNA
fragment from a randomly selected uracil prototrophic clone
(designated CRG20291) was PCR ampliﬁed using appropriate
primers (Table S1) and subjected to Sanger sequencing. This
conﬁrmed that the ermB gene and Pthl had inserted as intended,
immediately downstream of the restored pyrE gene. Accordingly,
CRG20291 was resistant to erythromycin (50 mg/ml). To determine
the sensitivity to clindamycin, freshly grown colonies on BHISunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. Comparative phenotypic properties of R20291 and CRG20291. a. Strains were
cultured for 72 h in BHIS and colony forming units (CFU) were determined by serial
dilutions and plating (shaded bars). The activity of the toxin production in cell culture
supernatants was determined by titrating out toxin activity on Vero cells (triangle
shapes). b. Virulence of C. difﬁcile strains in hamsters. Hamsters were challenged with
630 (n ¼ 8), R20291 (n ¼ 8) or R20291M (n ¼ 8). Time from infection to clinical
endpoint by each strain is presented in hours. The duration of the experiment was set
at 336 h. The open triangles were animals not found to be colonised at the end of the
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were re-streaked on to BHIS medium supplemented with clinda-
mycin. Plates were incubated anaerobically at 37 C for 24 h and the
MIC was designated as the lowest concentrationwhere growth was
inhibited. The MIC of CRG20191 had increased relative to R20291
(16 mg/ml) and was equivalent to that seen with the commonly
studied strain 630 (Table 1).
To ascertain that CRG20291 was phenotypically indistinguish-
able from R20291, strains were cultured anaerobically at 37 C in
BHIS media and the colony forming units determined over a 72 h
time period by plating appropriate dilutions onto BHIS agar. At the
same time-points, toxin A and toxin B activity were measured by
cell cytotoxicity assay [13] using Vero (African green monkey kid-
ney) and HT29 (Human colon carcinoma) cell monolayers. No sta-
tistical difference was observed between either the growth of the
two strains, or the amount of toxins produced (Fig. 1A). Similarly,
using the sporulation assay of Burns et al. [14], no difference in the
number of spores produced (data not shown) was evident
following growth for 5 days on BHIS agar supplemented with 0.5%
yeast extract (Sigma).
Finally, hamster infection studies were undertaken as previ-
ously described [9] in accordance with the UK Home Ofﬁce
Inspectorate under the Animals (Scientiﬁc Procedures) Act 1986
(see supplementary ﬁle for full details). Faecal and caecum samples
collected during the course of the experiment were homogenised,
heat treated and plated to look for the presence of C. difﬁcile. To
conﬁrm the C. difﬁcile isolated from these samples was the same
strain originally used during infection, DNA was isolated from
overnight cultures and PCR ampliﬁcation was carried out using
primer pairs speciﬁc to each host: 630 wild type: 4140 and 5880R;
R20291: CDSM0-239-F1 and CDSM0-239-R1, and; CRG20291: Cdi-
630-pyrD-sF1 and ermB-HindIII-R (see Table S1, for sequences).
Following infectionwith the R20291 parental strain of C. difﬁcile,
75% of the animals infected were found to be colonised and all of
these went on to show signs of infection, although the time from
infection to clinical end point was spread between 52 and 83 h post
infection (Fig. 1B). When strain 630 or CRG20291 were used for
infection, 100% of the animals were found to be colonised and all
went on to show signs of infectionwith 7 of the 8 animals reaching
a clinical end point between either 44 and 72 h post infection (630)
or 44 h post infection (CRG20291). The remaining animals went on
to develop signs of infection and reached a clinical end point at
either 91 h (630) or 76 h (CRG20291) post infection. The CRG20291
infected animals (Fig. 1B) reached the clinical deﬁned end point
21.8 h earlier than the animals infected with R20291 (p ¼ 0.0086)Table 1
Clindamycin MICs for C. difﬁcile strains 630, R20291 and CRG20291.
Clindamycin (mg/ml) C. difﬁcile strains
630 (WT) 630Derm R20291 CRG20291
0 þþ þþ þþ þþ
0.1 þþ þþ þþ þþ
1 þþ þþ þþ þþ
10 þþ þþ þþ þþ
12 þþ þþ þþ þþ
14 þþ þþ þþ þþ
16 þþ þ þ þþ
18 þþ e e þþ
20 þþ e e þþ
30 þþ e e þþ
40 þ e e þþ
50 e e e þ
80 e e e e
100 e e e e
þþ growth observed, þ weak growth observed, e no growth observed.
experiment. All statistical analyses were performed using the GraphPad Prism 5
(GraphPad Prism Software). Student t-tests were carried out followed by a Mann
Whitney test to determine signiﬁcant difference between groups of animals. P
values  0.05 were considered signiﬁcant.and 16 h earlier than the animals infected with the 630 wild type
strain (p ¼ 0.0184).
The diversity in times to clinical end point observed in the
R20291 strain and the incomplete colonisation recorded is most
likely a result of the strains sensitivity to the antibiotic clinda-
mycin (MIC ¼ 16 mg/ml) [6]. It has previously been shown that 8
days following administration of a single 30 mg/kg dose of clin-
damycin, the antibiotic could be isolated at levels of 9 mg/g from
the intestinal tract of hamsters. The levels recovered could
be sufﬁcient to inhibit colonisation with the sensitive R20291
strain [7].
Here we have shown that the introduction of an ermB gene into
R20291 confers on the strain created, CRG20291, increased resis-
tance to erythromycin and clindamycin which leads to 100% colo-
nisation in the hamster model and a reduction in the time from
M.L. Kelly et al. / Anaerobe 39 (2016) 51e53 53infection to clinical end point by 21.8 h compared to R20291. The
reproducible colonisation and mortality rates observed with
CRG20291 will allow for direct comparison of a “wild type” strain
with any ClosTron generated mutants.
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